Close Menu

NEW YORK (GenomeWeb) – Personal Genome Diagnostics announced today that it has signed a co-development agreement with PathGroup for the PGDx Elio tissue-based complete assay.

As part of the agreement, the firms will partner on the necessary studies to support and secure US regulatory approval for the Elio tissue complete assay. PathGroup said it plans to be the first US laboratory to use the Elio panel.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.